S

Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399

Watchlist Manager
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
Watchlist
Price: 10.8 CNY -5.1% Market Closed
Market Cap: 13.5B CNY
Have any thoughts about
Shenzhen Hepalink Pharmaceutical Group Co Ltd?
Write Note

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Short-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Short-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
S
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
Short-Term Investments
ÂĄ333.4m
CAGR 3-Years
-6%
CAGR 5-Years
-1%
CAGR 10-Years
79%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Short-Term Investments
ÂĄ2.4B
CAGR 3-Years
-36%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Short-Term Investments
ÂĄ279.3m
CAGR 3-Years
2 201%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Short-Term Investments
ÂĄ973.2m
CAGR 3-Years
-34%
CAGR 5-Years
-36%
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Short-Term Investments
ÂĄ2.2B
CAGR 3-Years
-41%
CAGR 5-Years
-23%
CAGR 10-Years
15%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Glance View

Market Cap
13.5B CNY
Industry
Pharmaceuticals

Shenzhen Hepalink Pharmaceutical Group Co Ltd is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Shenzhen, Guangdong and currently employs 2,046 full-time employees. The company went IPO on 2010-05-06. Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based pharmaceutical company focused on the field of heparin sodium preparations and raw materials, macromolecular drugs contract development manufacturing organization (CDMO) and innovative drug development. The Company’s main products and services include enoxaparin sodium preparations and heparin sodium bulk medicines, enoxaparin sodium bulk medicines, and CDMO services for macromolecular drugs. The firm distributes its products within the domestic market and to overseas markets, including Turkey, Brazil, the United States and others.

Intrinsic Value
12.99 CNY
Undervaluation 17%
Intrinsic Value
Price
S

See Also

What is Shenzhen Hepalink Pharmaceutical Group Co Ltd's Short-Term Investments?
Short-Term Investments
333.4m CNY

Based on the financial report for Sep 30, 2024, Shenzhen Hepalink Pharmaceutical Group Co Ltd's Short-Term Investments amounts to 333.4m CNY.

What is Shenzhen Hepalink Pharmaceutical Group Co Ltd's Short-Term Investments growth rate?
Short-Term Investments CAGR 10Y
79%

Over the last year, the Short-Term Investments growth was -30%. The average annual Short-Term Investments growth rates for Shenzhen Hepalink Pharmaceutical Group Co Ltd have been -6% over the past three years , -1% over the past five years , and 79% over the past ten years .

Back to Top